<?xml version="1.0" encoding="UTF-8"?>
<p>Combination drugs are gaining importance and progress in pharmaceutical technology as they act on multi-mode targets responsible for the cause of AD. These products increase clinical effectiveness, reduce administrative costs, and enhance the patientsâ€™ adherence capacity. Further, the plants 
 <italic>A. catechu</italic>, 
 <italic>A. calamus</italic>, and 
 <italic>E. alba,</italic> which possess potential neuroprotective properties, may provide for an efficient yet sustainable pharmaceutical practice if considered for combinational therapies of AD after a detailed mechanistic evaluation.
</p>
